Kai Huang, Qianyi Zhang, Hao Ruan, Chunyu Guo, Shuyang Wu, Qinyi Liu, Deqiang Zhang, Shida Long, Wenrui Wang, Zhou Wu, Li Tian, Shuangyan Gao, Huanan Zhao, Xiaoting Gu, Huijun Yin, Cheng Yang
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with a high mortality rate and limited treatment efficacy. Nintedanib, a tyrosine kinase inhibitor, is clinically used to treat pulmonary fibrosis. At present, only nintedanib is on the market for the treatment of pulmonary fibrosis. Pazopanib is a drug for the treatment of renal cell carcinoma and advanced soft tissue sarcoma. METHODS: In this study, we explored whether pazopanib can attenuate bleomycin (BLM)-induced pulmonary fibrosis and explored its antifibrotic mechanism...
April 30, 2024: Journal of Thoracic Disease